CSF3 and acute myeloid leukemia: The CAG regimen, initially used by researchers in Japan, consists of low-dose cytarabine, low-dose aclarubicin, and G-CSF (47, 48), and has shown similar or better response/survival with lower treatment-related toxicity in AML and MDS patients (49–52).